Skip to content

Efficacy and Safety Comparison of Sleeve Gastrectomy versus Tirzepatide in Treating Patients with Severe Obesity: A Prospective Clinical Study

Efficacy and Safety Comparison of Sleeve Gastrectomy versus Tirzepatide in Treating Patients with Severe Obesity: A Prospective Clinical Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114246
Enrollment
Unknown
Registered
2025-12-09
Start date
2025-12-15
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Interventions

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-70 years old, BMI>=37.5kg/m^2 2. Be eligible for Bariatric surgery (LSG) according to ASMBS/IFSO 2022 guidelines 3.Diagnosis of insulin resistance (HOMA-IR>2.69) or type 2 diabetes mellitus (HOMA-IR=FPG×FINS/22.5). 4. Signed the informed consent and had the complete follow-up data of our hospital.

Exclusion criteria

Exclusion criteria: 1. Confirmed diagnosis of non-obese type 1 diabetes mellitus. 2. Patients with gestational diabetes or certain specific types of diabetes. 3. Substance abuse, alcohol addiction, or uncontrolled psychiatric disorders. 4. Intellectual disability or cognitive immaturity impairing behavioral control. 5. Unrealistic expectations regarding surgical weight loss outcomes. 6. Unwillingness to accept potential surgical complications. 7. Inability to comply with postoperative dietary/lifestyle modifications (poor adherence). 8. Poor systemic condition precluding general anesthesia or surgery tolerance. 9. Personal/family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 syndrome (MEN2). 10. Known severe hypersensitivity to tirzepatide or any excipient. 11. Previous gastrointestinal surgery (gastric/duodenal) or metabolic/bariatric surgery. 12. Active gastrointestinal ulceration. 13. Untreated Helicobacter pylori infection. 14. History of severe cardiovascular/cerebrovascular diseases (myocardial infarction, stroke, etc.). 15. History of liver cirrhosis (Child-Pugh score >= Grade A). 16. History of chronic kidney disease (estimated Glomerular Filtration Rate [eGFR] = Grade A.

Design outcomes

Primary

MeasureTime frame
Total Weight Loss Percentage (TWL%);Excess Weight Loss Percentage (EWL%);Gastrointestinal Quality of Life Index;Gastroesophageal reflux disease score;

Secondary

MeasureTime frame
Remission Rate of Type 2 Diabetes [glycated hemoglobin (HbA1c) 30 days) complications;Operative Time;Mean hospitalization duration;Hospitalization days from surgery (operative day = D0) to discharge;SF-36 questionnaire;IWQOL-Lite-CT questionnaire;

Countries

China

Contacts

Public ContactChen Yi

West China Hospital of Sichuan University

toddychan@163.com+86 138 8182 3928

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026